Switch to:
Also traded in: Argentina, Austria, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.33
PFE's Cash-to-Debt is ranked lower than
75% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. PFE: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
PFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.78 Max: N/A
Current: 0.33
Equity-to-Asset 0.35
PFE's Equity-to-Asset is ranked lower than
84% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. PFE: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.47 Max: 0.66
Current: 0.35
0.35
0.66
Interest Coverage 11.61
PFE's Interest Coverage is ranked lower than
71% of the 638 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.48 vs. PFE: 11.61 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.27  Med: 10.39 Max: 18.94
Current: 11.61
5.27
18.94
Piotroski F-Score: 6
Altman Z-Score: 2.30
Beneish M-Score: -2.58
WACC vs ROIC
7.48%
13.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 26.25
PFE's Operating Margin % is ranked higher than
89% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. PFE: 26.25 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 14.53  Med: 23.82 Max: 29.44
Current: 26.25
14.53
29.44
Net Margin % 13.92
PFE's Net Margin % is ranked higher than
75% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. PFE: 13.92 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.67  Med: 16.8 Max: 42.65
Current: 13.92
12.67
42.65
ROE % 11.92
PFE's ROE % is ranked higher than
67% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. PFE: 11.92 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.29  Med: 11.86 Max: 27.93
Current: 11.92
9.29
27.93
ROA % 4.29
PFE's ROA % is ranked higher than
54% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. PFE: 4.29 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.36 Max: 12.3
Current: 4.29
4.05
12.3
ROC (Joel Greenblatt) % 59.08
PFE's ROC (Joel Greenblatt) % is ranked higher than
86% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.07 vs. PFE: 59.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 40.74  Med: 57.28 Max: 82.01
Current: 59.08
40.74
82.01
3-Year Revenue Growth Rate 4.70
PFE's 3-Year Revenue Growth Rate is ranked lower than
53% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. PFE: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.5  Med: 7.3 Max: 19.2
Current: 4.7
-2.5
19.2
3-Year EBITDA Growth Rate -10.10
PFE's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. PFE: -10.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 8 Max: 36.8
Current: -10.1
-10.1
36.8
3-Year EPS without NRI Growth Rate -10.80
PFE's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. PFE: -10.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: 5.6 Max: 90.5
Current: -10.8
-26.8
90.5
GuruFocus has detected 4 Warning Signs with Pfizer Inc $PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:NVSEF, OTCPK:RHHBY, NYSE:MRK, NYSE:SNY, NYSE:ABBV, OTCPK:BAYZF, OTCPK:GLAXF, NYSE:BMY, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHF, NAS:HCM » details
Traded in other countries:PFE.Argentina, PFE.Austria, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, 0Q1N.UK,
Headquarter Location:USA
Pfizer Inc is a research-based biopharmaceutical company. The Company's portfolio includes medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing over 50% of its total sales.

Top Ranked Articles about Pfizer Inc

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas that offer returns of 18% or more!
Nasdaq Reports Another New High Dow Jones and S&P 500 report losses for the day
U.S. market indexes were mixed on Tuesday with the Nasdaq reporting another new high. Read more...
Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy
Covered Call reports for Apple, Coty Inc., NVIDIA, Pfizer Inc. and Yelp include trade ideas that offer returns of 21% or more!
Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy
FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Investors: Covered Call reports for Exelixis, Facebook, Priceline, Pfizer Inc. and AT&T include trade ideas that offer returns of 18% or more!
Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease

Ratios

vs
industry
vs
history
PE Ratio 28.36
NYSE:PFE's PE Ratio is ranked lower than
52% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.96 vs. NYSE:PFE: 28.36 )
Ranked among companies with meaningful PE Ratio only.
NYSE:PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 16.52 Max: 34.77
Current: 28.36
7.68
34.77
Forward PE Ratio 13.25
NYSE:PFE's Forward PE Ratio is ranked higher than
75% of the 68 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.46 vs. NYSE:PFE: 13.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 28.12
NYSE:PFE's PE Ratio without NRI is ranked lower than
51% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.64 vs. NYSE:PFE: 28.12 )
Ranked among companies with meaningful PE Ratio without NRI only.
NYSE:PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.83  Med: 19.38 Max: 34.43
Current: 28.12
9.83
34.43
Price-to-Owner-Earnings 17.91
NYSE:PFE's Price-to-Owner-Earnings is ranked higher than
74% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. NYSE:PFE: 17.91 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NYSE:PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.44  Med: 10.82 Max: 36.49
Current: 17.91
5.44
36.49
PB Ratio 3.44
NYSE:PFE's PB Ratio is ranked lower than
59% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. NYSE:PFE: 3.44 )
Ranked among companies with meaningful PB Ratio only.
NYSE:PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.44 Max: 3.72
Current: 3.44
1.32
3.72
PS Ratio 3.93
NYSE:PFE's PS Ratio is ranked lower than
59% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. NYSE:PFE: 3.93 )
Ranked among companies with meaningful PS Ratio only.
NYSE:PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.6 Max: 4.74
Current: 3.93
1.72
4.74
Price-to-Free-Cash-Flow 15.19
NYSE:PFE's Price-to-Free-Cash-Flow is ranked higher than
73% of the 209 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.35 vs. NYSE:PFE: 15.19 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NYSE:PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 13.13 Max: 18.91
Current: 15.19
5.02
18.91
Price-to-Operating-Cash-Flow 13.20
NYSE:PFE's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.13 vs. NYSE:PFE: 13.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NYSE:PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 11.73 Max: 15.89
Current: 13.2
4.55
15.89
EV-to-EBIT 23.28
NYSE:PFE's EV-to-EBIT is ranked lower than
58% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.48 vs. NYSE:PFE: 23.28 )
Ranked among companies with meaningful EV-to-EBIT only.
NYSE:PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.5 Max: 28.8
Current: 23.28
6.7
28.8
EV-to-EBITDA 14.61
NYSE:PFE's EV-to-EBITDA is ranked higher than
59% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.55 vs. NYSE:PFE: 14.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
NYSE:PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.3 Max: 17.3
Current: 14.61
4.9
17.3
Shiller PE Ratio 21.31
NYSE:PFE's Shiller PE Ratio is ranked higher than
79% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.91 vs. NYSE:PFE: 21.31 )
Ranked among companies with meaningful Shiller PE Ratio only.
NYSE:PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.12  Med: 16.72 Max: 25.32
Current: 21.31
9.12
25.32
Current Ratio 1.44
NYSE:PFE's Current Ratio is ranked lower than
74% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. NYSE:PFE: 1.44 )
Ranked among companies with meaningful Current Ratio only.
NYSE:PFE' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.53 Max: 3.18
Current: 1.44
0.98
3.18
Quick Ratio 1.14
NYSE:PFE's Quick Ratio is ranked lower than
71% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. NYSE:PFE: 1.14 )
Ranked among companies with meaningful Quick Ratio only.
NYSE:PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.23 Max: 2.86
Current: 1.14
0.74
2.86
Days Inventory 225.46
NYSE:PFE's Days Inventory is ranked lower than
86% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. NYSE:PFE: 225.46 )
Ranked among companies with meaningful Days Inventory only.
NYSE:PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 229.24 Max: 344.63
Current: 225.46
185.33
344.63
Days Sales Outstanding 61.70
NYSE:PFE's Days Sales Outstanding is ranked higher than
62% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. NYSE:PFE: 61.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
NYSE:PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 69.5 Max: 106.89
Current: 61.7
56.83
106.89
Days Payable 103.66
NYSE:PFE's Days Payable is ranked higher than
70% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.86 vs. NYSE:PFE: 103.66 )
Ranked among companies with meaningful Days Payable only.
NYSE:PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 115.45 Max: 179.46
Current: 103.66
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.67
NYSE:PFE's Dividend Yield % is ranked higher than
88% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. NYSE:PFE: 3.67 )
Ranked among companies with meaningful Dividend Yield % only.
NYSE:PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.7 Max: 10.4
Current: 3.67
2.9
10.4
Dividend Payout Ratio 1.03
NYSE:PFE's Dividend Payout Ratio is ranked lower than
77% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. NYSE:PFE: 1.03 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NYSE:PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.77 Max: 1.08
Current: 1.03
0.58
1.08
3-Year Dividend Growth Rate 7.70
NYSE:PFE's 3-Year Dividend Growth Rate is ranked higher than
53% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. NYSE:PFE: 7.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NYSE:PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.6 Max: 22.6
Current: 7.7
-14.7
22.6
Forward Dividend Yield % 3.79
NYSE:PFE's Forward Dividend Yield % is ranked higher than
89% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.71 vs. NYSE:PFE: 3.79 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.49
NYSE:PFE's 5-Year Yield-on-Cost % is ranked higher than
87% of the 846 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.18 vs. NYSE:PFE: 5.49 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NYSE:PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.34  Med: 5.54 Max: 15.57
Current: 5.49
4.34
15.57
3-Year Average Share Buyback Ratio 1.70
NYSE:PFE's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. NYSE:PFE: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NYSE:PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: 0.1 Max: 7.2
Current: 1.7
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.09
NYSE:PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. NYSE:PFE: 1.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NYSE:PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.45 Max: 9.98
Current: 1.09
0.53
9.98
Price-to-Median-PS-Value 1.09
NYSE:PFE's Price-to-Median-PS-Value is ranked lower than
51% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. NYSE:PFE: 1.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NYSE:PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 1.06 Max: 3.31
Current: 1.09
0.43
3.31
Earnings Yield (Greenblatt) % 4.29
NYSE:PFE's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. NYSE:PFE: 4.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NYSE:PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.5  Med: 6.9 Max: 14.9
Current: 4.29
3.5
14.9
Forward Rate of Return (Yacktman) % 2.61
NYSE:PFE's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 381 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. NYSE:PFE: 2.61 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NYSE:PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.5  Med: 12.45 Max: 23.3
Current: 2.61
2.5
23.3

More Statistics

Revenue (TTM) (Mil) $52,599.00
EPS (TTM) $ 1.19
Beta1.06
Short Percentage of Float0.77%
52-Week Range $29.83 - 37.39
Shares Outstanding (Mil)6,399.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 52,870 53,942 53,367
EPS ($) 2.54 2.73 2.80
EPS without NRI ($) 2.54 2.73 2.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.01%
Dividends per Share ($) 1.28 1.36 1.45

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}